Key result
Recent data suggest cardiotoxicity from anti-HER2 therapy is rare, supporting a focused cardiac surveillance strategy rather than routine serial echocardiography for all patients.
Why the study?
Does a focused cardiac surveillance strategy reduce the burden of repetitive echocardiography and false-positive results compared to current FDA recommendations in low-risk patients receiving anti-HER2 chemotherapy?
Does a focused cardiac surveillance strategy reduce the burden of repetitive echocardiography and false-positive results compared to current FDA recommendations in low-risk patients receiving anti-HER2 chemotherapy?
A more focused cardiac surveillance strategy is advocated for low-risk patients on anti-HER2 therapy to avoid the burden and false positives of repetitive echocardiography.
Surveillance of left ventricular function, part of current US Food and Drug Administration recommendations for anti-human epidermal growth factor receptor 2 (anti-HER2) chemotherapy, is based on historical data involving patients who received concomitant anthracycline therapy, a key enhancer of cardiac risk. More recent anti-HER2 treatment data suggest that cardiotoxicity detected by screening is rare and usually benign for patients who do not have cardiovascular risk factors and are not taking an anthracycline. Because of the burden of repetitive echocardiography required for surveillance and the risk of false-positive results, potentially leading to discontinuing lifesaving treatment, we advocate for a more focused cardiac surveillance strategy.
No takes yet. Share an insight, caveat, or question.
Collier et al. (2021) conducted a review in HER2-positive breast cancer. Cardiac surveillance was evaluated. Recent data suggest cardiotoxicity from anti-HER2 therapy is rare, supporting a focused cardiac surveillance strategy rather than routine serial echocardiography for all patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: